106017-08-7

Basic information

• Product Name: Rufloxacin hydrochloride
• Synonyms: RUFLOXACIN HCL;RUFLOXACIN HYDROCHLORIDE;7h-pyrido(1,2,3-de)(1,4)benzothiazine-6-carboxylicacid,2,3-dihydro-9-fluoro-1;mf-934;RUFLOXACINHYDROCHLORIDE(SUBJECTTOPATENTFREE);2,3-Dihydro-9-fluoro-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de][1,4]benzothiazine-6-carboxylic acid hydrochloride;7H-Pyrido[1,2,3-de]-1,4-benzothiazine-6-carboxylicacid, 9-fluoro-2,3-dihydro-10-(4-methyl-1-piperazinyl)-7-oxo-, hydrochloride(1:1)
• CAS NO: 106017-08-7
• Molecular Formula: C17H19ClFN3O3S
• Molecular Weight: 399.87
• Mol File: 106017-08-7.mol

Chemical Properties

• Melting Point: 322-324℃
• Boiling Point: 574.6 °C at 760 mmHg
• Flash Point: 301.3 °C
• Appearance: /
• Storage Temp.: -20°C Freezer, Under inert atmosphere
• Solubility: DMSO (Slightly, Heated), Water (Very Slightly)
• CAS DataBase Reference: Rufloxacin hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: Rufloxacin hydrochloride(106017-08-7)
• EPA Substance Registry System: Rufloxacin hydrochloride(106017-08-7)

Safety Data

• Hazardous Substances Data: 106017-08-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Rufloxacin hydrochloride is used as an antibiotic for the treatment of various bacterial infections, particularly respiratory and urinary tract infections, as well as chronic bacterial prostatitis. Its effectiveness in inhibiting hOCT1 makes it a valuable addition to the arsenal of antibiotics for combating resistant bacterial strains.
Used in Research and Development:
Rufloxacin hydrochloride is used as a research compound for studying the mechanisms of action and interactions of fluoroquinolone antibiotics with human organic cation transporters. This knowledge can contribute to the development of new drugs with improved efficacy and reduced side effects.
Brand Names:
Rufloxacin hydrochloride is available under the brand names Qari and Monos, which are marketed for the treatment of the aforementioned infections.

Originator

Mediolanum (Italy)

InChI:InChI=1/C17H18FN3O3S.ClH/c1-19-2-4-20(5-3-19)14-12(18)8-10-13-16(14)25-7-6-21(13)9-11(15(10)22)17(23)24;/h8-9H,2-7H2,1H3,(H,23,24);1H

Upstream product

• 108860-30-6 ethyl 2,3,5-trifluoro-4-(4-methyl-1-piperazinyl)-benzoyl acetate 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 
• 60-23-1 Cysteamine 
• 138944-12-4 ethyl 2-<2,3,5-trifluoro-4-(4-methyl-1-piperazinyl)-benzoyl>-3-(1-mercaptoeth-2-ylamino)-acrylate 
• 113933-55-4 ethyl 2-<2,3,5-trifluoro-4-(4-methyl-1-piperazinyl)-benzoyl>-3-dimethylaminoacrylate 
• 138944-13-5 ethyl 9-fluoro-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido<1,2,3-de><1,4>benzothiazine-6-carboxylate 

Related news

Optimization and validation of a CZE method for Rufloxacin hydrochloride (cas 106017-08-7) determination in coated tablets07/20/2019

A simple and rapid capillary electrophoresis method with UV detection was developed and validated for the determination of rufloxacin hydrochloride in coated tablets. An experimental design strategy (Doehlert design and desirability function) allowed the analytical parameters to be simultaneousl...detailed

Relevant articles and documents

QUINOLINE DISULFIDES AS INTERMEDIATES

A process for preparing rufloxacin using a compound of the formula I (I) as a starting material is described, where R is herein defined.

Process for the preparation of rufloxacin and salts thereof

A process for the preparation of rufloxacin, a compound of the formula I STR1 and salts thereof is described. This is effected by reducing a quinoline disulfide of formula (II) as herein defined, and subjecting the resulting 2-mercaptoethyl quinoline of formula (III) as herein defined to a cyclization in a basic medium and hydrolyzing the rufloxacin ester thus obtained and, if desired, forming the salts thereof.

Quinilone disulfide as intermediates

A process for preparing rufloxacin using a compound of the formula I STR1 as a starting material is described, where R is herein defined.

Process for the preparation of 9-fluoro-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzothiazine-6-carboxylic acid hydrochloride

Process for the preparation of 9-fluoro-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido [1,2,3-de][1,4]benzothiazine-6-carboxylic acid hydrochloride (Rufloxacin) of formula (I) by reaction of 2,3,5-trifluoro-4-(4-methyl-1-piperazinyl)benzoyl ethyl acetate of formula (II) with N,N-dimethylformamide dimethylacetal, followed by reaction with 2-aminoethanethiol, intramolecular cyclization by treatment with NaH, hydrolysis with H2O and salification with HCl.

Process for the preparation of 9-fluoro-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzothiazine-6-carboxylic acid hydrochloride

Process for the preparation of 9-fluoro-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzothiazine-6-carboxylic acid hydrochloride (Rufloxacin) by reaction of 2,3,5-trifluoro-4-(4-methyl-1-piperazinyl)benzoyl ethyl acetate with N,N-dimethylformamide dimethylacetal, followed by reaction with 2-aminoethanethiol, intramolecular cyclization by treatment with NaH, hydrolysis with H2 O and salification with HCl.

One-pot synthesis of rufloxacin

Rufloxacin (MF-934) was prepared in one-pot synthesis in 61% yield by treatment of the 2,3,5-trifluoro-4-(4-methyl-1-piperazinyl)-benzoyl acetate, first with N,N-dimethylformamide dimethyl acetal, then with 2-aminoethanethiol, followed by cyclization and